Evidence map›Paper›PMID 39358486›Full record

ArticleAAPS PharmSciTech2024

Docetaxel-tethered di-Carboxylic Acid Derivatised Fullerenes: A Promising Drug Delivery Approach for Breast Cancer.

Charu Misra, Jasleen Kaur, Manish Kumar, Lokesh Kaushik, Deepak Chitkara, Simran Preet, Muhammad Wahajuddin, Kaisar Raza

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Charu MisraDepartment of Pharmacy, School of Chemical Science and Pharmacy, Central University of Rajasthan, Bandarsindri, Distt. Ajmer, Rajasthan, 305817, India.
Jasleen KaurDepartment of Biophysics, Panjab University, Chandigarh, 160 014, India.
Manish KumarDepartment of Pharmacy, School of Chemical Science and Pharmacy, Central University of Rajasthan, Bandarsindri, Distt. Ajmer, Rajasthan, 305817, India.
Lokesh KaushikDepartment of Pharmacy, School of Chemical Science and Pharmacy, Central University of Rajasthan, Bandarsindri, Distt. Ajmer, Rajasthan, 305817, India.
Deepak ChitkaraDepartment of Pharmacy, Birla Institute of Technology and Science, Pilani, Rajasthan, 33031, India.
Simran PreetDepartment of Biophysics, Panjab University, Chandigarh, 160 014, India.
Muhammad WahajuddinInstitute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, Richmond Road, Bradford, BD7 1DP, UK.
Kaisar RazaDepartment of Pharmacy, School of Chemical Science and Pharmacy, Central University of Rajasthan, Bandarsindri, Distt. Ajmer, Rajasthan, 305817, India. drkaisar@curaj.ac.in.ORCID http://orcid.org/0000-0001-8159-8005

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Docetaxel (DTX) has become widely accepted as a first-line treatment for metastatic breast cancer; however, the frequent development of resistance provides challenges in treating the disease.C

Indexed as

Antineoplastic AgentsBreast NeoplasmsCarboxylic AcidsCell SurvivalDocetaxelDrug Delivery SystemsFullerenesAnimalsBiological AvailabilityCell Line, TumorDrug CarriersDrug LiberationFemaleHumansMCF-7 CellsNanoconjugatesAntineoplastic AgentsCarboxylic AcidsDocetaxelDrug CarriersFullerenesNanoconjugatesanti-cancerbioavailabilitybiocompatibilitydrug conjugationdrug deliveryfullereneshydrophilic linker

Identifiers

PMID39358486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.